Methylthioninium Chloride Proveblue
Methylene blue – Antidote for methemoglobinemia
Methylthioninium chloride Proveblue (commonly known as methylene blue) is a prescription medicine administered by intravenous injection for the acute treatment of drug-induced and chemical-induced methemoglobinemia in adults and children. It acts as an electron carrier that restores the oxygen-carrying capacity of hemoglobin. This medication is used exclusively in hospital and emergency settings under the supervision of qualified healthcare professionals.
Quick Facts
Key Takeaways
- Methylthioninium chloride Proveblue is the first-line antidote for symptomatic methemoglobinemia, restoring hemoglobin's ability to carry oxygen to tissues.
- It is administered only intravenously in hospital settings at a dose of 1–2 mg/kg body weight, injected slowly over 5 minutes.
- The drug is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as it may worsen methemoglobinemia and cause hemolytic anemia.
- Methylthioninium chloride is a potent MAO inhibitor and can cause life-threatening serotonin syndrome when combined with serotonergic medications such as SSRIs and SNRIs.
- Blue-green discoloration of urine and skin is an expected, harmless side effect that resolves within 24–72 hours after administration.
What Is Methylthioninium Chloride Proveblue and What Is It Used For?
Methylthioninium chloride, widely known by its common name methylene blue, has been used in clinical medicine for well over a century. First synthesized in 1876 by the German chemist Heinrich Caro, it was originally developed as a textile dye. Its medical applications were discovered in the late 19th century, making it one of the oldest synthetic drugs still in active clinical use. Today, its primary authorized indication is the acute treatment of symptomatic methemoglobinemia caused by drugs or chemicals.
Methemoglobinemia is a condition in which hemoglobin in the blood is oxidized from its normal ferrous (Fe2+) state to the ferric (Fe3+) state, forming methemoglobin. Unlike normal hemoglobin, methemoglobin cannot bind and transport oxygen effectively. When methemoglobin levels rise above 20–30% of total hemoglobin, patients develop significant symptoms including cyanosis (bluish discoloration of the skin), shortness of breath, fatigue, confusion, and in severe cases, seizures, coma, and death.
Proveblue is the EMA-approved brand name for pharmaceutical-grade methylthioninium chloride solution for injection. It was specifically developed to provide a high-purity formulation free from potentially harmful impurities found in some industrial-grade methylene blue preparations. Proveblue is manufactured under strict Good Manufacturing Practice (GMP) conditions and has been authorized in the European Union since 2011 as an orphan medicinal product.
Mechanism of Action
Methylthioninium chloride acts as an artificial electron carrier in the NADPH-methemoglobin reductase pathway. When administered intravenously, the drug enters red blood cells, where it is reduced by NADPH and the enzyme methemoglobin reductase (also known as diaphorase II) to form leucomethylene blue (leucomethylthioninium chloride). This reduced form, leucomethylene blue, is a potent reducing agent that non-enzymatically reduces methemoglobin (Fe3+) back to functional hemoglobin (Fe2+), thereby restoring the blood's oxygen-carrying capacity.
This reduction cycle can occur repeatedly, as the oxidized methylene blue produced is again reduced by NADPH to leucomethylene blue. It is important to note that this pathway is entirely dependent on the availability of NADPH, which is generated by the hexose monophosphate shunt (pentose phosphate pathway). This explains why the drug is ineffective and potentially dangerous in patients with G6PD deficiency, who cannot generate sufficient NADPH.
Authorized Indications
The primary authorized indication for methylthioninium chloride Proveblue is the acute symptomatic treatment of drug-induced and chemical-induced methemoglobinemia. Common causes of acquired methemoglobinemia that may require treatment include:
- Local anesthetics: benzocaine, prilocaine, lidocaine (especially topical preparations used in high doses)
- Antimicrobial agents: dapsone, trimethoprim-sulfamethoxazole, chloroquine
- Nitrites and nitrates: sodium nitrite, amyl nitrite, nitroglycerin, contaminated well water
- Industrial chemicals: aniline dyes, nitrobenzene, naphthalene (mothballs)
- Recreational substances: alkyl nitrites (poppers), certain synthetic drugs
In addition to methemoglobinemia treatment, methylthioninium chloride has several investigational and off-label uses, including as a surgical dye for intraoperative visualization (such as sentinel lymph node mapping), a diagnostic stain for fistula tract identification, and in experimental studies for the treatment of ifosfamide-induced encephalopathy and certain neurodegenerative conditions. However, these uses are outside the approved indications for Proveblue.
What Should You Know Before Taking Methylthioninium Chloride Proveblue?
As a hospital-administered injectable medication, methylthioninium chloride Proveblue is always given under direct medical supervision. However, both patients and healthcare professionals should be aware of critical safety information, contraindications, and warnings associated with this drug. The decision to administer methylthioninium chloride requires a careful benefit-risk assessment, especially in patients with certain comorbidities or who are taking concomitant medications.
Contraindications
Methylthioninium chloride Proveblue must not be used in the following situations:
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency lack sufficient NADPH to reduce methylene blue to its active form. Administration may paradoxically worsen methemoglobinemia and trigger severe hemolytic anemia, which can be fatal. G6PD deficiency affects approximately 400 million people worldwide and is particularly prevalent in populations of African, Mediterranean, and Southeast Asian descent.
- Hypersensitivity: Known allergy to methylthioninium chloride, other thiazine dyes, or any of the excipients in the formulation.
- Methemoglobinemia caused by chlorate poisoning: In chlorate poisoning, the methemoglobin is in a form that cannot be reduced by leucomethylene blue. Additionally, chlorates cause Heinz body hemolytic anemia, and methylene blue may worsen hemolysis.
- Nitrite-induced methemoglobinemia during cyanide treatment: When nitrites are intentionally administered as part of a cyanide poisoning antidote regimen, methylene blue would counteract the therapeutic methemoglobinemia that is protecting against cyanide toxicity.
Warnings and Precautions
Methylthioninium chloride is a potent, reversible inhibitor of monoamine oxidase A (MAO-A). When used with serotonergic drugs, it can precipitate serotonin syndrome, a potentially life-threatening condition characterized by mental status changes, autonomic instability, neuromuscular abnormalities, and hyperthermia. The FDA and EMA have issued specific warnings about this risk.
Additional warnings and precautions include:
- Renal impairment: Methylthioninium chloride is primarily excreted by the kidneys. Reduced renal function may lead to accumulation and increased risk of toxicity. Dose reduction should be considered in patients with moderate renal impairment, and the drug should be avoided in severe renal insufficiency.
- Paradoxical methemoglobinemia: At high doses (typically >7 mg/kg), methylthioninium chloride can itself act as an oxidizing agent and paradoxically worsen methemoglobinemia. This dose-dependent reversal of its therapeutic effect is clinically significant.
- Photosensitivity: Methylthioninium chloride is a photosensitizing agent. Patients should avoid prolonged exposure to direct sunlight or artificial UV light during and immediately after treatment, as severe phototoxic skin reactions may occur.
- Neonates and infants: Use in neonates (particularly preterm neonates) requires extreme caution due to lower G6PD activity, immature renal function, and higher susceptibility to methemoglobin formation. The risk of hemolytic anemia and central nervous system toxicity is significantly elevated in this population.
- Pulse oximetry interference: Methylene blue causes falsely low pulse oximetry (SpO2) readings because it absorbs light at wavelengths used by standard pulse oximeters. Co-oximetry (arterial blood gas analysis) is required for accurate monitoring of methemoglobin levels and oxygen saturation during and after treatment.
Pregnancy and Breastfeeding
There are limited clinical data on the use of methylthioninium chloride during pregnancy. Animal studies have shown reproductive toxicity, including teratogenic effects at high doses. The drug should only be used during pregnancy if the clinical situation is life-threatening and no safer alternative is available. When used during delivery, neonates should be closely monitored for hemolytic anemia, methemoglobinemia, and other adverse effects.
It is not known whether methylthioninium chloride or its metabolites are excreted in human breast milk. As a precaution, breastfeeding should be discontinued during treatment and for at least 8 days following administration of the drug. The long elimination half-life of the drug and its metabolites necessitates this extended precaution.
How Does Methylthioninium Chloride Interact with Other Drugs?
Drug interactions with methylthioninium chloride can be both pharmacodynamic and pharmacokinetic in nature. The most clinically significant interactions relate to its potent monoamine oxidase A (MAO-A) inhibitory activity and its effects on methemoglobin levels. Healthcare professionals must perform a thorough medication review before administering this drug, especially in emergency situations where the patient's full medication history may not be immediately available.
Major Interactions
| Drug / Drug Class | Interaction Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) | MAO-A inhibition by methylthioninium chloride increases serotonin levels | Serotonin syndrome (potentially fatal) | Discontinue SSRI 2–5 weeks before (depending on half-life) or closely monitor |
| SNRIs (venlafaxine, duloxetine, desvenlafaxine) | MAO-A inhibition increases serotonin and norepinephrine | Serotonin syndrome | Discontinue at least 1 week before or closely monitor |
| MAO inhibitors (phenelzine, tranylcypromine, moclobemide) | Additive MAO inhibition | Severe serotonin syndrome, hypertensive crisis | Contraindicated; wait at least 2 weeks after MAOI discontinuation |
| Tricyclic antidepressants (amitriptyline, clomipramine, imipramine) | Serotonergic activity combined with MAO-A inhibition | Serotonin syndrome | Avoid if possible; monitor closely if essential |
| Serotonin 5-HT1 agonists (triptans: sumatriptan, rizatriptan) | Additive serotonergic effects | Serotonin syndrome | Avoid concomitant use |
| Opioids (fentanyl, tramadol, meperidine/pethidine) | Serotonergic activity of certain opioids | Serotonin syndrome | Use alternative analgesics; avoid tramadol and meperidine |
Minor Interactions
| Drug / Drug Class | Interaction | Recommendation |
|---|---|---|
| Dapsone | May cause methemoglobinemia; methylthioninium chloride treats this but dapsone can cause recurring elevation | Repeated doses of methylthioninium chloride may be needed; monitor methemoglobin levels |
| Photosensitizing drugs (tetracyclines, fluoroquinolones) | Additive photosensitivity risk | Protect patient from UV exposure |
| Methemoglobin-inducing agents (nitrites, local anesthetics) | May reduce the efficacy of methylthioninium chloride or require repeated dosing | Identify and remove the causative agent when possible |
| Reducing agents (ascorbic acid) | May have additive effect in reducing methemoglobin | Can be used as adjunctive therapy in mild cases |
Healthcare professionals should monitor for the following signs of serotonin syndrome for up to 4 hours after methylthioninium chloride administration: mental status changes (agitation, confusion, delirium), autonomic instability (tachycardia, blood pressure fluctuations, hyperthermia, diaphoresis), and neuromuscular abnormalities (myoclonus, hyperreflexia, tremor, rigidity). Onset is usually rapid, within minutes to hours of drug exposure.
What Is the Correct Dosage of Methylthioninium Chloride Proveblue?
Methylthioninium chloride Proveblue is supplied as a 5 mg/ml solution for injection in 10 ml ampoules (50 mg per ampoule). It must be diluted with 50 ml of glucose 50 mg/ml (5%) solution before administration and injected intravenously over a period of 5 minutes. Rapid injection should be avoided as it may cause local pain and blue discoloration of the tissue surrounding the injection site. The drug must never be administered by subcutaneous or intrathecal routes.
Adults
Standard Adult Dosage
Initial dose: 1–2 mg/kg body weight (typically 0.2–0.4 ml/kg of the 5 mg/ml solution), administered as a slow intravenous injection over 5 minutes.
Repeat dose: If methemoglobin levels remain elevated or symptoms persist after 30–60 minutes, a second dose of 1–2 mg/kg may be administered.
Maximum cumulative dose: 7 mg/kg. Exceeding this dose significantly increases the risk of paradoxical methemoglobinemia and toxicity.
Example: For a 70 kg adult, the initial dose would be 70–140 mg (14–28 ml of the 5 mg/ml solution).
Children
Pediatric Dosage
Children and adolescents (3 months to 17 years): 1–2 mg/kg body weight, administered as a slow intravenous injection over 5 minutes. The same dosing principles as adults apply.
Neonates and infants below 3 months: The recommended dose is 0.3–0.5 mg/kg, administered as a slow intravenous injection. Extreme caution is required due to the immature enzyme systems and higher risk of toxicity in this population. Neonates, particularly preterm infants, are more vulnerable to the oxidant effects of methylene blue due to lower G6PD activity and reduced methemoglobin reductase activity.
Elderly
Elderly Dosage
No specific dose adjustments are recommended solely based on age. However, elderly patients are more likely to have reduced renal function, which may affect drug clearance. Renal function should be assessed, and dosage adjustments considered accordingly. Elderly patients are also more likely to be taking serotonergic medications, increasing the risk of serotonin syndrome.
Renal Impairment
Dosage in Renal Impairment
Mild to moderate impairment: Use with caution and consider a dose reduction. Monitor the patient for prolonged effects and signs of toxicity.
Severe impairment (eGFR <30 ml/min): Methylthioninium chloride Proveblue should be avoided if possible. If use is considered essential and no alternative is available, administer at the lowest effective dose with intensive monitoring.
Missed Dose
As methylthioninium chloride Proveblue is administered in hospital settings as acute treatment for a life-threatening condition, the concept of a missed dose does not typically apply. The drug is given in response to clinical symptoms and methemoglobin levels, and repeat dosing is based on the clinical response. Treatment decisions are made in real time by the attending physician based on the patient's clinical status and laboratory results.
Overdose
Overdose (particularly doses exceeding 7 mg/kg) can cause paradoxical methemoglobinemia (the drug itself becomes an oxidizing agent), hemolytic anemia, dyspnea, chest pain, restlessness, tremor, and blue-green discoloration of the skin. Large overdoses may cause nausea, vomiting, abdominal pain, precordial pain, dizziness, confusion, headache, profuse sweating, and in severe cases, cardiovascular collapse and death.
Treatment of overdose is supportive and symptomatic. There is no specific antidote for methylthioninium chloride overdose. In severe cases, exchange transfusion may be necessary. Hyperbaric oxygen therapy may also be considered if methemoglobin levels remain dangerously elevated despite supportive measures.
What Are the Side Effects of Methylthioninium Chloride Proveblue?
Like all medicines, methylthioninium chloride can cause side effects, although not everybody gets them. The side effect profile of methylthioninium chloride reflects its pharmacological activity as a redox-active dye and MAO inhibitor. Many of the observed adverse effects are dose-dependent and more likely to occur at higher doses or with prolonged administration. Healthcare professionals should be aware that some side effects, particularly discoloration, are expected pharmacological effects rather than adverse drug reactions.
Very Common (affects more than 1 in 10 people)
- Blue-green discoloration of urine (expected; lasts 24–72 hours)
- Chromaturia (colored urine)
- Blue discoloration of the skin and mucous membranes
- Pain, swelling, or irritation at the injection site
Common (affects 1 in 10 to 1 in 100 people)
- Nausea and vomiting
- Abdominal pain
- Chest pain or chest discomfort
- Headache
- Dizziness
- Sweating (hyperhidrosis)
- Paresthesia (tingling or numbness)
- Taste disturbance (dysgeusia)
Uncommon (affects 1 in 100 to 1 in 1,000 people)
- Hemolytic anemia (particularly in G6PD-deficient patients)
- Anxiety and confusion
- Tremor
- Hypertension or hypotension
- Tachycardia
- Dyspnea (shortness of breath)
- Photosensitivity reactions
Rare (affects fewer than 1 in 1,000 people)
- Serotonin syndrome (when combined with serotonergic drugs)
- Paradoxical methemoglobinemia (at high doses >7 mg/kg)
- Severe skin necrosis (if extravasation occurs during injection)
- Anaphylactic or anaphylactoid reactions
- Fever
- Severe hemolytic anemia with renal failure
- Pulmonary edema
Patients should be monitored using co-oximetry (not standard pulse oximetry, which gives falsely low readings in the presence of methylene blue). Methemoglobin levels should be checked at baseline and at regular intervals after administration. If symptoms do not improve or worsen after the initial dose, consider G6PD deficiency, recheck methemoglobin levels, or evaluate for alternative diagnoses. The blue discoloration of skin and urine is expected and does not require treatment.
How Should You Store Methylthioninium Chloride Proveblue?
Methylthioninium chloride Proveblue should be stored according to the manufacturer's specifications to ensure the integrity and potency of the product. As this medication is used exclusively in hospital and clinical settings, storage is typically managed by hospital pharmacies under established protocols.
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze.
- Light protection: Keep the ampoules in the original outer carton to protect from light. Methylene blue is photosensitive and can degrade when exposed to prolonged light.
- After opening: The product is for single use only. Any unused solution remaining in the ampoule after use must be discarded immediately. Do not store opened ampoules for later use.
- After dilution: The diluted solution should be used immediately. Chemical and physical in-use stability has been demonstrated for up to 6 hours at 25°C when diluted with glucose 5% solution.
- Shelf life: 36 months (3 years) from the date of manufacture when stored under the recommended conditions. Do not use after the expiry date stated on the ampoule label and carton.
- Disposal: Dispose of unused medicine or waste material in accordance with local requirements for hospital pharmaceutical waste.
The solution should be inspected visually before use. Methylthioninium chloride Proveblue is a clear, dark blue solution. Do not use if the solution appears cloudy, contains particles, or if the ampoule appears damaged. As with all injectable preparations, the solution should be checked against a white and a black background for clarity and particulate matter.
What Does Methylthioninium Chloride Proveblue Contain?
Methylthioninium chloride Proveblue is designed as a high-purity pharmaceutical product. The simplified formulation reflects the critical need for a clean, well-characterized injection solution, particularly important given that earlier non-pharmaceutical-grade methylene blue preparations contained potentially harmful impurities including heavy metals, organic contaminants, and other thiazine dye-related substances.
Active Substance
- Methylthioninium chloride: 5 mg per ml. Each 10 ml ampoule contains 50 mg of methylthioninium chloride. The chemical formula is C16H18ClN3S, and its molecular weight is 319.85 g/mol. It is also known by its INN (International Nonproprietary Name) as methylthioninium chloride, and commonly known as methylene blue.
Excipients
- Water for injections: Serves as the solvent. Prepared to pharmacopoeial grade to ensure sterility and freedom from pyrogens.
The product does not contain preservatives, antimicrobial agents, or any other excipients. This minimal formulation reduces the risk of excipient-related adverse effects and allergic reactions. The solution has a pH of approximately 3.0–4.5.
Physical Characteristics
The solution is a clear, dark blue liquid. When diluted as directed, it produces a blue solution. The dark blue color of the undiluted solution is characteristic of the oxidized form of methylthioninium chloride. Upon reduction in the body to leucomethylene blue, it becomes colorless, although this process occurs intracellularly and is not visible in the administered solution.
Frequently Asked Questions About Methylthioninium Chloride Proveblue
Methylthioninium chloride Proveblue is used as an antidote for the acute treatment of drug-induced and chemical-induced methemoglobinemia in adults and children. Methemoglobinemia is a condition where hemoglobin in the blood is oxidized and can no longer carry oxygen effectively. Common causes include exposure to certain local anesthetics (benzocaine, prilocaine), antibiotics (dapsone), nitrites, and industrial chemicals. The drug is administered by intravenous injection in hospital or emergency settings only.
Methylthioninium chloride acts as an electron carrier in the NADPH-methemoglobin reductase pathway inside red blood cells. When injected, it is reduced by the enzyme NADPH-methemoglobin reductase to leucomethylene blue. This reduced form then non-enzymatically converts methemoglobin (which cannot carry oxygen) back to normal hemoglobin (which can carry oxygen). This process restores the blood's oxygen-carrying capacity and relieves the symptoms of methemoglobinemia. The response is usually rapid, with improvement seen within 30–60 minutes.
No. Methylthioninium chloride is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with G6PD deficiency cannot generate enough NADPH (which is produced by the G6PD-dependent pentose phosphate pathway) to reduce methylene blue to its active form. Without sufficient NADPH, the drug cannot work and may instead act as an oxidizing agent, paradoxically worsening methemoglobinemia and causing severe hemolytic anemia. Alternative treatments for methemoglobinemia in G6PD-deficient patients include intravenous ascorbic acid (vitamin C) at high doses or exchange transfusion in severe cases.
Blue-green discoloration of urine is an expected and harmless effect of methylthioninium chloride. The drug is a dark blue dye that is excreted primarily through the kidneys. As it is filtered out of the blood, it colors the urine blue or blue-green. This discoloration typically persists for 24–72 hours after administration, depending on the dose given and the patient's kidney function. The skin, sclera (whites of the eyes), and mucous membranes may also appear bluish temporarily. This is not harmful and resolves on its own as the drug is cleared from the body.
Yes, and this is one of the most critical drug interactions. Methylthioninium chloride is a potent reversible inhibitor of monoamine oxidase A (MAO-A), the enzyme that breaks down serotonin. When combined with serotonergic drugs such as SSRIs (fluoxetine, sertraline, citalopram), SNRIs (venlafaxine, duloxetine), tricyclic antidepressants, or MAO inhibitors, it can cause serotonin syndrome – a potentially life-threatening condition with symptoms including agitation, confusion, rapid heart rate, high blood pressure, high body temperature, muscle rigidity, and seizures. The FDA and EMA have both issued safety communications warning about this interaction. Ideally, serotonergic drugs should be stopped before methylthioninium chloride is given, though in emergency situations this may not be possible.
All information is based on international medical guidelines and peer-reviewed research: the European Medicines Agency (EMA) Summary of Product Characteristics for Proveblue, the U.S. Food and Drug Administration (FDA) approved labeling for methylene blue injection, World Health Organization (WHO) Model List of Essential Medicines, the British National Formulary (BNF), Goldfrank's Toxicologic Emergencies (reference toxicology textbook), and published clinical studies and systematic reviews in peer-reviewed journals. Evidence levels follow the GRADE framework, with the highest priority given to systematic reviews of randomized controlled trials (Level 1A evidence).
References
This article is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Proveblue – Summary of Product Characteristics (SmPC). EMA/CHMP, last updated 2024. Available at: ema.europa.eu/proveblue
- U.S. Food and Drug Administration (FDA). Provayblue (methylene blue) Injection – Prescribing Information. FDA, 2016. Available at: accessdata.fda.gov
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. WHO, Geneva, 2023.
- Clifton J, Leikin JB. Methylene blue. American Journal of Therapeutics. 2003;10(4):289-291. doi:10.1097/00045391-200307000-00009
- Bradberry SM. Occupational methemoglobinemia: mechanisms of production, features, diagnosis and management including the use of methylene blue. Toxicological Reviews. 2003;22(1):13-27. doi:10.2165/00139709-200322010-00003
- Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology. 2007;152(6):946-951. doi:10.1038/sj.bjp.0707430
- U.S. FDA Drug Safety Communication. Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. FDA, July 2011 (updated October 2020).
- Goldfrank LR, et al. Goldfrank's Toxicologic Emergencies. 11th Edition. McGraw-Hill Education, 2019. Chapter 127: Methemoglobin Inducers.
- British National Formulary (BNF). Methylthioninium chloride. NICE/BNF, accessed 2025. Available at: bnf.nice.org.uk
- Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Annals of Emergency Medicine. 1999;34(5):646-656. doi:10.1016/S0196-0644(99)70167-8
Editorial Team
This article has been researched, written, and medically reviewed by the iMedic Medical Editorial Team, which includes board-certified specialists in clinical pharmacology, toxicology, and emergency medicine.
iMedic Medical Editorial Team – Specialists in clinical pharmacology and drug safety with documented academic background and clinical experience.
iMedic Medical Review Board – Independent panel of medical experts who review all content according to international guidelines (EMA, FDA, WHO, BNF).
Editorial Standards: All medical information follows the iMedic Editorial Standards and the GRADE evidence framework. Content is reviewed at least annually and updated when new clinical evidence or guideline changes are published. No pharmaceutical company funding or sponsorship.